Amarin Corporation (AMRN) Q3 2026 earnings summary

Executive summary

• First profitable quarter in over two years, with lower operating expenses, positive operating cash flow and $323.4M in cash and short-term investments.

• International partner demand grew strongly while U.S. generic competition and pricing pressure weighed on revenue.

Financial highlights

• Q3 revenue was $39.6M, down 20% YoY; product revenue fell 24% to $36.9M, while licensing and royalty revenue rose 139% to $2.7M.

• Net income was $245K versus a $7.7M net loss; operating loss narrowed to $2.4M from $11.1M.

• Operating expenses fell 44% to $18.5M; 9M operating expenses declined 47% to $74.6M.

• 9M revenue was $126.9M, down 23%; net loss narrowed to $17.9M from $37.6M.

• 9M operating cash flow was $22.2M versus $8.5M used in the prior-year period; Q3 operating cash flow was $9.2M.

Outlook and guidance

• Positive operating cash flow expected for FY 2026, with Q4 cash flow expected to remain positive and further operating expense reductions anticipated, excluding restructuring charges.

• U.S. volumes expected to remain broadly stable through year-end 2026; significant exclusive business expected to be retained through year-end.

• Global partner-market demand is expected to grow sequentially; revenue timing depends on partner inventory, orders, market access and pricing.

• Singapore and South Korea launches are anticipated in 2027; regulatory approvals in the Philippines, Thailand, Vietnam and Malaysia are anticipated by 2030.